about
P3780
Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With IpilimumabPhase III Trial of (LCT) After Nivolumab and IpilimumabCorneal ulceration associated with Nivolumab useNivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell CarcinomaA Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaTadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck CancerIpilimumab and Nivolumab as Adjuvant Treatment of Mucosal MelanomaStudy of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid TumorsStudy of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic CancerA Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
P921
Q63807898-510EE376-3728-4591-BA38-45DD68C264BEQ63807919-843E4CE9-AB9D-492D-AFD7-CD8BA6AB77BBQ64140145-FE9D6333-C7DF-4433-A938-6838382584D9Q64151073-4FC8D861-E575-436B-BAF3-C5180BEFA641Q64186954-53CFEF59-DD21-4FDC-96BA-CBAE474B15CBQ64246978-62CF2759-4919-4F63-BFF9-95B235706E89Q64790777-735B77C2-B271-4E21-8A8B-F1C9B8F50E05Q64793618-0F960EB3-A54A-481C-A8BA-0785AAD3D0E4Q64818591-267831A3-0374-4FA0-AD5F-C2449097B016Q66063711-3CD4F95D-CA44-4C27-8363-30155CB51DE0Q66068949-6E0279DD-EE2E-4E62-949A-950D48BE087DQ66078729-D48F8710-A2B7-4A7D-90E1-00EB3AFBC7A7Q66400623-F21E02D4-53EC-483B-BEDD-57A536EBE39FQ67128504-3F52DC0B-3DA3-4E7A-BB40-0A4DE5EEDB2AQ80365452-C7A6002A-678E-4B51-B7C8-19344C99D194Q96056027-28AB57E5-B13D-42D8-8D2D-A05BBC75AB29
P921
description
pharmaceutical product
@en
name
Opdivo
@en
type
label
Opdivo
@en
prefLabel
Opdivo
@en
P4044
P3345
P3637
EMEA/H/C/003985